Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Decreased by SG Americas Securities LLC

Posted by Francis Steltz on Jun 26th, 2026

SG Americas Securities LLC trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 39.4% during the first quarter, HoldingsChannel.com reports. The fund owned 55,060 shares of the biopharmaceutical company’s stock after selling 35,861 shares during the period. SG Americas Securities LLC’s holdings in Alnylam Pharmaceuticals were worth $18,218,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $25,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $27,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $32,000. Finally, Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 0.3%

NASDAQ:ALNY opened at $293.17 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $273.11 and a fifty-two week high of $495.55. The stock’s 50-day moving average is $297.10 and its two-hundred day moving average is $332.36. The stock has a market cap of $39.14 billion, a PE ratio of 80.10 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.44) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,740 shares of company stock worth $2,420,214 over the last ninety days. 0.86% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on ALNY shares. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 21st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $463.13.

Check Out Our Latest Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.